Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin - Novartis

Drug Profile

Ciclosporin - Novartis

Alternative Names: Ciclosporin microemulsion - Novartis; Cyclosporin A microemulsion - Novartis; Cyclosporin microemulsion - Novartis; Cyclosporin modified - Novartis; Cyclosporine microemulsion - Novartis; Neoral; OLO400; Sandimmun Neoral; Sandimmune Neoral

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Erasmus MC; Novartis
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis; Heart transplant rejection; Liver transplant rejection; Myasthenia gravis; Pancreas transplant rejection; Psoriasis; Renal transplant rejection; Rheumatoid arthritis; Transplant rejection
  • Discontinued Ulcerative colitis

Most Recent Events

  • 12 Jul 2016 No development reported - Phase-I for Psoriasis in Netherlands (Topical)
  • 30 Jul 2014 Discontinued - Phase-II for Ulcerative colitis in England (PO)
  • 30 Sep 2007 Preregistration for Atopic dermatitis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top